Cognizant (CTSH) Form 144: Proposed Sale of 6,965 Common Shares
Rhea-AI Filing Summary
Form 144 filing for Cognizant Technology Solutions (CTSH) reports a proposed sale of 6,965 shares of Common stock through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $504,823.20. The filing lists total shares outstanding as 488,395,937 and an approximate sale date of 08/28/2025. The shares were acquired in four transactions: restricted stock on 06/02/2021 (2,787 shares) and 06/06/2024 (885 shares), and exercised shares on 05/27/2021 (2,609 shares) and 05/17/2022 (684 shares). The filer states there were no securities sold in the past three months and includes the required representation that the selling person knows of no undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider intends to sell a small block of shares worth ~$505k; transaction appears routine and non-material to company valuation.
The notice documents a proposed sale of 6,965 common shares through a broker, representing roughly 0.0014% of the reported outstanding shares (6,965 of 488,395,937). Acquisition dates span 2021–2024 and include restricted stock grants and option exercises, indicating the shares derive from typical compensation events rather than an external purchase. There are no reported sales in the prior three months. From a market-impact perspective, the size of the sale relative to total shares outstanding is negligible; the filing contains standard Rule 144 certifications but no new operational or financial information about the issuer.
TL;DR: Filing is a standard insider sale notice with customary representations; it raises no governance red flags on its face.
The Form 144 lists the broker, number of shares, acquisition history, and sale date, and includes the signature representation required under Rule 144. The mix of restricted stock and exercised shares is consistent with executive compensation vesting and option exercises. The absence of recent sales in the prior three months is noted. The document does not disclose any adopted trading plan or 10b5-1 instruction date; no material adverse information is asserted. Based solely on the filing, there are no governance concerns evident.